ライフサイエンスコーパス: Plasmodium falciparum

1 s are vectors of the human malaria parasite, Plasmodium falciparum.

2 bition assays with proteasomes isolated from Plasmodium falciparum.

3 d by Controlled Human Malaria Infection with Plasmodium falciparum.

4 of the most virulent human malaria parasite, Plasmodium falciparum.

5 ethal form of malaria in humans is caused by Plasmodium falciparum.

6 ogue from the human malaria-causing parasite Plasmodium falciparum.

7 an important role in asexual development of Plasmodium falciparum.

8 a-erythrocytic forms of the malaria parasite Plasmodium falciparum.

9 cosylation reactions, in the blood stages of Plasmodium falciparum.

10 s Laverania, one of which gave rise to human Plasmodium falciparum.

11 array data of host antibody response against Plasmodium falciparum.

12 ionary success of the human malaria parasite Plasmodium falciparum.

13 ntial and conserved in the malaria parasite, Plasmodium falciparum.

14 ed significant antimalarial activity against Plasmodium falciparum.

15 most prevalent in cerebral malaria caused by Plasmodium falciparum.

16 g the asexual stages of the malaria parasite Plasmodium falciparum.

17 fe-cycle stage of the human malaria parasite Plasmodium falciparum.

18 e and the non-model human malarial parasite, Plasmodium falciparum.

19 nsi) to transmit the human malaria parasite, Plasmodium falciparum.

20 s in the life cycle of the malaria parasite, Plasmodium falciparum.

21 ated by mosquito bite: a major challenge for Plasmodium falciparum.

22 th regions, R0 and R2), and AMA1 antigens of Plasmodium falciparum.

23 nosoma brucei rhodesiense and falcipain-2 of Plasmodium falciparum.

24 mission blocking vaccine (TBV) candidate for Plasmodium falciparum.

25 of DNA replication throughout schizogony in Plasmodium falciparum.

26 Also present were Plasmodium vivax (14.3%), Plasmodium falciparum (10.5%) and Plasmodium malariae (3

27 vity and alkylate the molecular target(s) of Plasmodium falciparum 3D7 parasites in situ.

28 Treatment of Plasmodium falciparum 3D7 parasites with peptide corresp

29 ays, the compounds show growth inhibition of Plasmodium falciparum 3D7 with IC50 approximately 1 muM.

30 evaluated as noteworthy growth inhibitors of Plasmodium falciparum (3D7 and W2) in culture.

31 phenotypic screen against the blood stage of Plasmodium falciparum (3D7) and displayed moderate poten

32 (s) within the asexual erythrocytic stage of Plasmodium falciparum (3D7).

33 A cryo-electron microscopy structure of the Plasmodium falciparum 80S ribosome with the (+)-mefloqui

34 CR-HRM results to the species level revealed Plasmodium falciparum (92.0%), Plasmodium ovale (5.6%),

35 For Plasmodium falciparum, a causative agent of human malari

36 dverse pregnancy and birth outcomes owing to Plasmodium falciparum accumulation in the placenta.

37 ae s.s. mosquitoes are efficient vectors for Plasmodium falciparum, although variation exists in thei

38 In the present study antibody responses to Plasmodium falciparum AMA-1, MSP-119 and CSP were measur

39 dium vivax populations are more diverse than Plasmodium falciparum and identify signs of recent selec

40 y are present in at least nine proteins from Plasmodium falciparum and one from Plasmodium knowlesi W

41 source-use strategies to the human parasites Plasmodium falciparum and P. vivax: P. chabaudi and P. f

42 in only two of five human-infecting species: Plasmodium falciparum and Plasmodium knowlesi.

43 racterize parasite density distributions for Plasmodium falciparum and Plasmodium vivax, and the prop

44 two main species causing malaria in humans, Plasmodium falciparum and Plasmodium vivax, rely on two

45 genome variation data of Anopheles gambiae, Plasmodium falciparum and Plasmodium vivax.

46 The malaria parasite Plasmodium falciparum and related apicomplexan pathogens

47 Plasmodium falciparum and Toxoplasma gondii are widely s

48 es the two related human parasitic pathogens Plasmodium falciparum and Toxoplasma gondii.

49 in 112 volunteers infected with blood-stage Plasmodium falciparum and treated with 8 different antim

50 laria is caused by the Apicomplexan parasite Plasmodium falciparum, and results in significant global

51 We sought to identify a subset of Plasmodium falciparum antibody targets that would inform

52 In this study, we further assessed the Plasmodium falciparum antigen upregulated in infective s

53 munity, which may influence the emergence of Plasmodium falciparum artemisinin-resistant phenotypes a

54 its single-digit nanomolar inhibition of the Plasmodium falciparum asexual blood stages and transmiss

55 linical antimalarial drugs and inhibitors on Plasmodium falciparum asexual blood stages.

56 e cycle stages of the human malaria parasite Plasmodium falciparum (asexual and sexual) and Plasmodiu

57 CDPK1 is critical for asexual development of Plasmodium falciparum, but its precise function and subs

58 ted in great gains in reducing the burden of Plasmodium falciparum, but P. vivax has been more refrac

59 Suspected artemisinin resistance in Plasmodium falciparum can be explored by examining polym

60 continuous exposure to the malaria parasite Plasmodium falciparum cause an accumulation of specific

61 Plasmodium falciparum causes a spectrum of malarial dise

62 Plasmodium falciparum causes malaria in humans with over

63 Plasmodium falciparum causes most life-threatening cases

64 own whether these responses could engage the Plasmodium falciparum CelTOS in vivo Using a newly devel

65 vaccine candidate of malaria is based on the Plasmodium falciparum circumsporozoite protein (CSP), a

66 encing of 24 independently derived resistant Plasmodium falciparum clones revealed four parasites wit

67 associated with Epstein-Barr virus (EBV) and Plasmodium falciparum coinfection, although how P. falci

68 d on an imidazopyridine series targeting the Plasmodium falciparum cyclic GMP-dependent protein kinas

69 Among them, the Plasmodium falciparum Cysteine-Rich Protective Antigen (

70 The human malaria parasite, Plasmodium falciparum, depends on a coordinated regulati

71 do so by studying the resistance mediated by Plasmodium falciparum dihydrofolate reductase (DHFR) to

72 Plasmodium falciparum DNA from 183 samples collected pri

73 We assessed Plasmodium falciparum drug resistance markers in parasit

74 f BV and haem targets the phosphorylation of Plasmodium falciparum eIF2alpha factor, an eukaryotic in

75 Plasmodium falciparum encodes ten predicted SET domain-c

76 e-threatening complication of infection with Plasmodium falciparum Epidemiological observations have

77 Plasmodium falciparum erythrocyte membrane protein 1 (Pf

78 Plasmodium falciparum erythrocyte membrane protein 1 (Pf

79 ial activity against asexual blood stages of Plasmodium falciparum, excellent parasite selectivity, a

80 Plasmodium falciparum exports proteins into erythrocytes

81 d with uninfected controls, women with early Plasmodium falciparum exposure had retarded intrauterine

82 The equally ancient human malaria parasite, Plasmodium falciparum, formed an intimate relationship w

83 sed a long-term decline in the prevalence of Plasmodium falciparum from 40% prevalence in the period

84 We introduce Plasmodium falciparum gametocyte exported protein-5 (PfG

85 Deformability of Plasmodium falciparum gametocyte-infected erythrocytes (

86 Plasmodium falciparum gametocytes are essential for mala

87 Even submicroscopic levels of Plasmodium falciparum gametocytes can infect mosquitoes

88 st transcriptome analysis of male and female Plasmodium falciparum gametocytes coupled with a compreh

89 e expense and difficulty of producing mature Plasmodium falciparum gametocytes in vitro-the parasite

90 To address this challenge, a Plasmodium falciparum gamma-irradiated long-lived merozo

91 for targeted resequencing of a panel of six Plasmodium falciparum genes implicated in resistance to

92 For reasons that remain unknown, the Plasmodium falciparum genome has an exceptionally high A

93 Analysis of multiple Plasmodium falciparum genomes showed that ICAM-1-binding

94 In this article, we demonstrate that Plasmodium falciparum genomic DNA delivered to the cytos

95 n both our Plasmodium gallinaceum (>80%) and Plasmodium falciparum (>40%) models, an activity that wa

96 The malaria parasite Plasmodium falciparum has a great capacity for evolution

97 number in the plasmepsin II/III genes within Plasmodium falciparum has been associated with decreased

98 of red cell invasion by the malaria parasite Plasmodium falciparum has been possible.

99 Proteases of the malaria parasite Plasmodium falciparum have long been investigated as dru

100 arlier studies in the human malaria parasite Plasmodium falciparum have shown that pantothenate analo

101 f-of-concept, this sensor was used to detect Plasmodium falciparum histidine-rich protein 2 (PfHRP2),

102 iagnosis, with most using antibodies against Plasmodium falciparum histidine-rich protein 2 (PfHRP2).

103 was estimated from plasma concentrations of Plasmodium falciparum histidine-rich protein 2 (PfHRP2).

104 sfully demonstrated via (i) the detection of Plasmodium falciparum histidine-rich protein 2 antigen a

105 an amplified color change in the presence of Plasmodium falciparum histidine-rich protein 2 at a conc

106 Rapid diagnostic tests based on Plasmodium falciparum histidine-rich protein II (PfHRP-I

107 ntigen lateral flow malaria RDT that targets Plasmodium falciparum histidine-rich protein-II (HRPII)

108 Deletions of the Plasmodium falciparum hrp2 (pfhrp2) gene cause false-neg

109 Deletions of the Plasmodium falciparum hrp2 and hrp3 genes can affect the

110 cell screening in erythrocytic cocultures of Plasmodium falciparum identified a series of dihydroisoq

111 e recombinant strains inhibit development of Plasmodium falciparum in mosquitoes.

112 he current epidemic of artemisinin resistant Plasmodium falciparum in Southeast Asia is the result of

113 Emergence of drug resistant Plasmodium falciparum including artemisinin-tolerant par

114 , in which participants were inoculated with Plasmodium falciparum induced blood-stage malaria (IBSM)

115 Plasmodium falciparum-induced severe malaria remains a c

116 important immune effector mechanism against Plasmodium falciparum-infected erythrocytes (IE); howeve

117 Placental malaria is caused by Plasmodium falciparum-infected erythrocytes (IEs) that s

118 ted malaria commonly involves the binding of Plasmodium falciparum-infected erythrocytes to placental

119 variant antigen expressed on the surface of Plasmodium falciparum-infected erythrocytes.

120 L2 expression on blood dendritic cells, from Plasmodium falciparum-infected individuals, correlated w

121 of the healthy and diseased RBCs, including Plasmodium falciparum-infected RBCs (Pf-RBCs) and defect

122 rheologically impaired Plasmodium vivax- and Plasmodium falciparum-infected RBCs.

123 malaria is characterized by cytoadhesion of Plasmodium falciparum-infected red blood cells (Pf-iRBCs

124 emia measurement and stage determination for Plasmodium falciparum-infected red blood cells (Pf-iRBCs

125 ses in proinflammatory cytokine responses to Plasmodium falciparum-infected red blood cells (PfRBCs)

126 nts inhibited in vitro growth progression of Plasmodium falciparum-infected red blood cells.

127 Severe malaria due to Plasmodium falciparum infection causes nearly half a mil

128 Pregnancy-associated Plasmodium falciparum infection impacts the health of mo

129 e and confers significant protection against Plasmodium falciparum infection in humans.

130 previously identified to be associated with Plasmodium falciparum infection in natural Anopheles gam

131 7-SIRPalpha in the innate immune response to Plasmodium falciparum infection is unknown.

132 Severe malaria due to Plasmodium falciparum infection remains a serious threat

133 ral malaria (CM) is a severe complication of Plasmodium falciparum infection responsible for thousand

134 Plasmodium falciparum infection was assessed by blood sm

135 which targets the pre-erythrocytic stage of Plasmodium falciparum infection.

136 is a severe and often fatal complication of Plasmodium falciparum infection.

137 ral malaria (CM) is a severe complication of Plasmodium falciparum infection.

138 gulated in vaccinees who were protected from Plasmodium falciparum infection.

139 l malaria (HCM) is a serious complication of Plasmodium falciparum infection.

140 Ap) represents a potential strategy to clear Plasmodium falciparum infections and reduce the human pa

141 Chronic asymptomatic Plasmodium falciparum infections are common in endemic a

142 We therefore studied spatial distribution of Plasmodium falciparum infections to compare simulated ef

143 herapies are the first line of treatment for Plasmodium falciparum infections worldwide, but artemisi

144 During Plasmodium falciparum infections, erythrocyte-stage para

145 Single low-dose primaquine (PQ) reduces Plasmodium falciparum infectivity before it impacts game

146 nvasion of the most lethal malaria parasite, Plasmodium falciparum Inhibition of Ca(2+)-related pheno

147 p. has provided a powerful tool to transform Plasmodium falciparum into a genetically more tractable

148 sible for the most virulent form of malaria, Plasmodium falciparum, invade erythrocytes.

149 The malaria parasite Plasmodium falciparum invades human red blood cells by a

150 odies against merozoite proteins involved in Plasmodium falciparum invasion into the red blood cell p

151 For the malaria parasite Plasmodium falciparum, invasion of host red blood cells

152 lls infected with the human malaria parasite Plasmodium falciparum (iRBCs) adhere to the vascular end

153 otility of the apicomplexan malaria parasite Plasmodium falciparum is enabled by a multiprotein glide

154 Activity of pepstatin against cultured Plasmodium falciparum is highly variable depending on th

155 Antigenic variation in Plasmodium falciparum is mediated by the multicopy var g

156 Gene expression in Plasmodium falciparum is tightly regulated to ensure suc

157 However, the human malaria parasite, Plasmodium falciparum, is incapable of pyrimidine salvag

158 s at loci associated with drug resistance in Plasmodium falciparum isolated from subjects receiving D

159 In this observational study, we tested Plasmodium falciparum isolates from Myanmar, northeaster

160 ry adaptation in malaria parasites, clinical Plasmodium falciparum isolates were sampled from patient

161 t of PfRh5--the essential invasion ligand in Plasmodium falciparum--its surface properties are distin

162 The role of Plasmodium falciparum K13 mutations (a marker of artemis

163 activity of the benzoxaborole AN3661 against Plasmodium falciparum laboratory-adapted strains (mean I

164 sure of Africans to fatal pathogens, such as Plasmodium falciparum, Lassa Virus and Trypanosoma bruce

165 cladosporin is a nanomolar inhibitor of the Plasmodium falciparum lysyl-tRNA synthetase, and exhibit

166 te in Mozambican children with uncomplicated Plasmodium falciparum malaria 7 days after combination t

167 Plasmodium falciparum malaria detected at delivery in pe

168 PM increases MMc and that MMc alters risk of Plasmodium falciparum malaria during infancy.

169 a urine malaria test (UMT) for diagnosis of Plasmodium falciparum malaria in febrile patients.

170 As the prevalence of artemisinin-resistant Plasmodium falciparum malaria increases in the Greater M

171 Plasmodium falciparum malaria infection is associated wi

172 e most effective treatment for uncomplicated Plasmodium falciparum malaria infection.

173 Plasmodium falciparum malaria is a deadly infectious dis

174 Much of the virulence of Plasmodium falciparum malaria is caused by cytoadherence

175 Although the burden of Plasmodium falciparum malaria is gradually declining in

176 Mass drug administration for elimination of Plasmodium falciparum malaria is recommended by WHO in s

177 stereomers 5a and 5c showed activity against Plasmodium falciparum malaria parasites (IC50 approximat

178 Plasmodium falciparum malaria remains a devastating publ

179 Severe Plasmodium falciparum malaria remains a leading cause of

180 Plasmodium falciparum malaria remains a leading cause of

181 primary marker of artemisinin resistance in Plasmodium falciparum malaria that threatens the long-te

182 a mathematical model of the transmission of Plasmodium falciparum malaria to explore the potential e

183 ation therapy, might prevent transmission of Plasmodium falciparum malaria to mosquitoes.

184 ng progress has been seen with reductions in Plasmodium falciparum malaria transmission in some parts

185 Adults with Plasmodium falciparum malaria were randomized to receive

186 causal (ie, pre-erythrocytic) prophylaxis of Plasmodium falciparum malaria with prolonged activity wo

187 dely-recommended treatment for uncomplicated Plasmodium falciparum malaria worldwide.

188 group has relatively better protection from Plasmodium falciparum malaria, as reflected by fewer sym

189 ay of the current treatment of uncomplicated Plasmodium falciparum malaria, but ACT resistance is spr

190 ncy is believed to confer protection against Plasmodium falciparum malaria, but the precise nature of

191 howed modest efficacy of the vaccine against Plasmodium falciparum malaria, but was not powered to as

192 nce of the spatiotemporal prevalence of both Plasmodium falciparum malaria-attributable and non-malar

193 could be considered for rescue treatment for Plasmodium falciparum malaria.

194 rison to results of PCR for the detection of Plasmodium falciparum malaria.

195 therapy (ACT) is the first-line treatment of Plasmodium falciparum malaria.

196 could be considered for rescue treatment for Plasmodium falciparum malaria.

197 otect children from severe and uncomplicated Plasmodium falciparum malaria.

198 t on ART, all of whom required treatment for Plasmodium falciparum malaria.

199 bstantial reduction in deaths resulting from Plasmodium falciparum malaria.

200 most efficacious treatment of uncomplicated Plasmodium falciparum malaria.

201 w era in effectively treating drug-resistant Plasmodium falciparum malaria.

202 859 patients aged 6 months to 12 years with Plasmodium falciparum malaria.

203 eases and obesity, is associated with severe Plasmodium falciparum malaria.

204 biomarker associated with increased risk for Plasmodium falciparum-mediated cerebral malaria (CM).

205 transmission on maintenance of antibodies to Plasmodium falciparum merozoite antigens and infected er

206 Invasion of erythrocytes by Plasmodium falciparum merozoites is necessary for malari

207 In this article, we show that Plasmodium falciparum merozoites, the invasive form of b

208 In this report, we show that Plasmodium falciparum merozoites, the invasive form of t

209 The Plasmodium falciparum mitochondrion contains two enzymes

210 candidates have slowed the development of a Plasmodium falciparum multiantigen vaccine.

211 Western Cambodia is the epicentre of Plasmodium falciparum multidrug resistance and is facing

212 n humans lacking robust adaptive immunity to Plasmodium falciparum Nevertheless, the host may partly

213 malaria is a deadly outcome of infection by Plasmodium falciparum, occurring when parasite-infected

214 ge replication of the human malaria parasite Plasmodium falciparum occurs via schizogony, wherein dau

215 ture of >/=37.5 degrees C and infection with Plasmodium falciparum of >2500 parasites per cubic milli

216 5-12 years) who were naturally infected with Plasmodium falciparum or noninfected controls.

217 -Orp1 in the cytosol and the mitochondria of Plasmodium falciparum (P. falciparum) NF54-attB blood-st

218 at ICAM-1 forms catch bond interactions with Plasmodium falciparum parasite iRBCs.

219 ical (MBG) approach to detect hotspots using Plasmodium falciparum parasite prevalence and serologica

220 5 year time horizon for a range of levels of Plasmodium falciparum parasite prevalence in 2-10 year o

221 FREP1 in mosquito midguts facilitates Plasmodium falciparum parasite transmission.

222 vere complications of human infection by the Plasmodium falciparum parasite.

223 Plasmodium falciparum parasitemia was less frequent than

224 tages of chloroquine-sensitive and resistant Plasmodium falciparum parasites (IC50 1-5 nM) as well as

225 linical outcome of individuals infected with Plasmodium falciparum parasites depends on many factors

226 rge-scale molecular epidemiologic studies of Plasmodium falciparum parasites have provided insights i

227 nvestigating whether successful sporogony of Plasmodium falciparum parasites through to human-infecti

228 Plasmodium falciparum parasites, the causative agents of

229 oft X-ray tomography of mature intracellular Plasmodium falciparum parasites, we resolve intermediate

230 cacy of this front-line regimen for treating Plasmodium falciparum parasites.

231 reatened by the spread of drug resistance in Plasmodium falciparum parasites.

232 simultaneously enriches pLDH and HRPII from Plasmodium falciparum parasitized blood samples.

233 The best ligands inhibited Plasmodium falciparum (Pf) and Arabidopsis thaliana (At)

234 Antibodies against the central repeat of the Plasmodium falciparum (Pf) circumsporozoite protein (CSP

235 uanine phosphoribosyltransferase (HGPRT) and Plasmodium falciparum (Pf) hypoxanthine-guanine-xanthine

236 ntrolled human malaria infection (CHMI) with Plasmodium falciparum (Pf) parasites homologous to the v

237 Malaria caused by the protozoan parasite Plasmodium falciparum (Pf) remains a major public health

238 ly by immunization with radiation-attenuated Plasmodium falciparum (Pf) sporozoites (PfSPZ) inoculate

239 protein (CSP), the major surface antigen of Plasmodium falciparum (Pf) sporozoites, can protect from

240 ce transporter of the human malaria parasite Plasmodium falciparum, PfCRT, is an important determinan

241 The Plasmodium falciparum Pfs25 protein (Pfs25) is a leading

242 the VIT homologue from the malaria parasites Plasmodium falciparum (PfVIT) and Plasmodium berghei (Pb

243 Bicyclic azetidines targeting Plasmodium falciparum phenylalanyl-tRNA synthetase compr

244 an imidazopyridine that selectively targets Plasmodium falciparum PKG, inhibits blood stage parasite

245 temisinin resistance in the malaria parasite Plasmodium falciparum poses a major threat to the contro

246 Plasmodium falciparum prevalence determined by qPCR decr

247 y, is shown to serve a different function in Plasmodium falciparum, protecting ookinetes from the mos

248 that the Plasmodium yoelii orthologs of four Plasmodium falciparum proteins identified by an antibody

249 ical trials have almost entirely focussed on Plasmodium falciparum, providing a highly informative me

250 We show that the Plasmodium falciparum PSD can restore the essential func

251 of L-45 with the homologous Brd PfGCN5 from Plasmodium falciparum rationalizes the high selectivity

252 reatment of the symptomatic asexual stage of Plasmodium falciparum relies almost exclusively on artem

253 me engineering in the human malaria pathogen Plasmodium falciparum remains highly challenging.

254 eed for a highly efficacious vaccine against Plasmodium falciparum remains pressing.

255 f malaria are threatened by the emergence of Plasmodium falciparum resistance to artemisinins.

256 The emergence of Plasmodium falciparum resistant to frontline therapeutic

257 For instance, Plasmodium falciparum reticulocyte-binding protein homol

258 Plasmodium falciparum reticulocyte-binding protein homol

259 During the intraerythrocytic stage of Plasmodium falciparum's lifecycle, band 3 becomes tyrosi

260 Many genes of the malaria parasite Plasmodium falciparum show clonally variant expression r

261 ty in P. vivax relative to the more virulent Plasmodium falciparum species; regional populations of P

262 Plasmodium falciparum-specific antibodies declined simil

263 Plasmodium falciparum-specific antibody kinetics during

264 The performance of Plasmodium falciparum-specific histidine-rich protein 2-

265 Plasmodium falciparum sporozite (PfSPZ) Vaccine is a met

266 dicates that the prevalence and intensity of Plasmodium falciparum sporozoite infection is significan

267 A live-attenuated malaria vaccine, Plasmodium falciparum sporozoite vaccine (PfSPZ Vaccine)

268 Experimental inoculation of viable Plasmodium falciparum sporozoites administered with chem

269 rs underwent CHMI with a low or high dose of Plasmodium falciparum sporozoites.

270 Plasmodium falciparum stage V gametocytes are responsibl

271 The Plasmodium falciparum START protein PFA0210c (PF3D7_0104

272 artemisinin (ART)-sensitive (K13 wild-type) Plasmodium falciparum strain is exposed to ART derivativ

273 For Plasmodium falciparum, strain theory has been specifical

274 the PfEMP1 proteins of the malaria parasite, Plasmodium falciparum, tethering parasite-infected eryth

275 orozoite protein (CSP)-based vaccine against Plasmodium falciparum that contains 19 NANP repeats foll

276 ro development or replication of blood-stage Plasmodium falciparum The percentage of Plasmodium-infec

277 We found that the activation of DCs by Plasmodium falciparum, the main causative agent of human

278 Infections with Plasmodium falciparum, the most pathogenic of the Plasmo

279 ndemic countries move towards elimination of Plasmodium falciparum, the most virulent human malaria p

280 For Plasmodium falciparum, the most widespread and virulent

281 Population-based genome sequencing of Plasmodium falciparum, the parasite responsible for the

282 Plasmodium falciparum, the parasite that causes the dead

283 For Plasmodium falciparum, the species responsible for the m

284 XEL) found in malaria effector proteins from Plasmodium falciparum These findings imply a role for th

285 ombined an established mathematical model of Plasmodium falciparum transmission dynamics with epidemi

286 The goal to prevent Plasmodium falciparum transmission from humans to mosqui

287 vere falciparum malaria following nosocomial Plasmodium falciparum transmission in nonendemic Germany

288 al blood stage of the human malaria parasite Plasmodium falciparum undergoes remarkable biophysical c

289 exan parasites, such as the malaria parasite Plasmodium falciparum, use actomyosin-driven gliding mot

290 atus were tested at each antenatal visit for Plasmodium falciparum, using an RDT and polymerase chain

291 d B cell phenotypes and Abs specific for the Plasmodium falciparum vaccine candidate apical membrane

292 olates overexpressed specific members of the Plasmodium falciparum var gene/PfEMP1 (P. falciparum ery

293 s used for malaria treatment until resistant Plasmodium falciparum was identified.

294 this sensor in the human malarial parasite, Plasmodium falciparum, we have quantified cytosolic labi

295 of an infection with the protozoan parasite Plasmodium falciparum, which requires immediate treatmen

296 alaria research and control still prioritize Plasmodium falciparum while largely neglecting P. vivax.

297 howed strong antiplasmodial activity against Plasmodium falciparum with IC50 values of 1.84, 8.36, an

298 thenic acid (PA) is critical for survival of Plasmodium falciparum within human erythrocytes.

299 se areas would still have been infected with Plasmodium falciparum without intervention, leading to 7

300 any organisms including the malaria parasite Plasmodium falciparum, yet the full extent of acetylatio